Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review
Translational Breast Cancer Research · 2026-07 · 7 · 28-28
DOI: 10.21037/tbcr-25-29 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2026-07. Verfasst von Hitomi Sakai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan.
ORCID-Profile: Hitomi Sakai
Zitieren
APA
Sakai, H., & Tsurutani, J. (2026). Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review. Translational Breast Cancer Research, 7, 28-28. https://doi.org/10.21037/tbcr-25-29
Vancouver
Sakai H, Tsurutani J. Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review. Translational Breast Cancer Research. 2026;7:28-28. doi:10.21037/tbcr-25-29
BibTeX
@article{Sakai2026,
author = {Sakai, Hitomi and Tsurutani, Junji},
title = {Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review},
journal = {Translational Breast Cancer Research},
year = {2026},
volume = {7},
pages = {28--28},
doi = {10.21037/tbcr-25-29}
}
EUVIMED